https://www.selleckchem.com/products/BI6727-Volasertib.html PROSPERO registration ID CRD42020151106. The implications of molecular biomarkers 1/2 mutations and gene promoter methylation were evaluated for prognostic outcome of glioma patients. Glioma cases were analyzed for 1/2 mutations and promoter methylation by DNA sequencing and methylation-specific PCR, respectively. Mutations found in 1/2 genes totaled 63.4% (N=40) wherein 1 mutations were significantly associated with oligidendrioglioma (p=0.005) and astrocytoma (p=0.0002). 1 mutants presented more, 60.5% in promoter-methylated cases (p=0.03). 1 mutant cases had better survival for glioblastoma and oligodendrioglioma (log-rank p=0.01). Multivariate analysis confirmed better survival in methylation carriers (hazard ratio [HR] 0.59; p=0.031). Combination of both biomarkers showed better prognosis on temozolomide (p<0.05). 1/2 mutations proved independent prognostic factors in glioma and associated with methylation for better survival. IDH1/2 mutations proved independent prognostic factors in glioma and associated with MGMT methylation for better survival. A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs). The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay. The patients were recruited from March 2011 to December 2017. Kaplan-Meier plot showed that patients with elevated STK1p values had worse overall survival (OS), especially patients of early/middle stages. Multi-variable COX regression showed that STK1p value and combined treatment surgery+chemotherapy were independent prognostic factors for favorable OS. STK1p is helpful in predicting OS of early/middle stages (I-IIIA) NSCLCs patients following a nonrandomized individual adapted treatment, but is may be not recommended in advanced stages (IIIB+IV) of NSCLCs. STK1p is helpful in predict